对于小细胞肺癌的治疗:多中心国家早期接触计划的现实经验
Marliese Alexander1,2, Jennifer Rogers1, Sagun Parakh3,4
1Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Internal medicine journal
|February 19, 2024
概括
卢比内克丁在澳大利亚小细胞肺癌患者的后治疗中显示出有效性. 现实世界的数据表明,这种治疗的临床试验结果与临床试验结果相似.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 卢比内克丁是瘤转录抑制剂,在各种癌症中有效.
- 小细胞肺癌 (SCLC) 的治疗通常涉及基于的化疗.
研究的目的:
- 评估澳大利亚SCLC患者的卢比内克丁的临床疗效和耐受性.
- 评估在含疗法进展后的使用.
主要方法:
- 一个多中心的真实世界研究,涉及46名SCLC患者接受lurbinectedin单一治疗.
- 通过澳大利亚胸部癌症注册和生物库 (AURORA) 收集的数据.
- 使用Kaplan-Meier方法分析的无进展生存率 (PFS) 和总生存率 (OS).
主要成果:
- 卢比内克丁被用作二线 (83%) 或后期治疗,通常是在化疗免疫疗法 (87%) 之后.
- 观察到的毒性包括剂量修改 (17%),中断 (24%),高度毒性 (28%) 和住院治疗 (54%).
- 总体应答率为33%,疾病控制率为50%,PFS中位数为2.5个月,OS为4.5个月.
结论:
- 这一澳大利亚在SCLC后白金治疗中使用卢比内克丁的现实体验与临床试验结果一致.
- 卢比内克丁在现实环境中表现出类似的疗效和耐受性.
更多相关视频
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
10.6K
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
10.6K
相关概念视频
Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K
Treatment Resistant Cancers
2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
